Ear Infection Treatment Market Value Projected To Reach US$ 9.6 Billion By 2028 Covering Covid-19 Impact: Acumen Research and Consulting
August 05, 2021 11:10 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Ear Infection Treatment Market– Global Industry Analysis, Market Size,...
Ear Nose and Throat (ENT) Treatment Market Value Surpass To Reach US$ 30.2 Billion By 2028 Covering Covid-19 Analysis: Acumen Research and Consulting
August 03, 2021 10:20 ET
|
Acumen Research and Consulting
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The Global Ear, Nose, and Throat (ENT) Treatment Market is expected to grow at a CAGR of around 5.5% from 2021 to 2028 and expected to reach around US$...
Cross Keys Capital Advises Atlanta Allergy & Asthma Clinic on Partnership with Southern Ear, Nose, Throat & Allergy Partners
September 30, 2020 17:59 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Florida, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive M&A advisor to Atlanta Allergy & Asthma Clinic ("Atlanta Allergy") in its partnership...
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
September 10, 2020 18:00 ET
|
Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
September 03, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET
|
Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
August 04, 2020 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
July 30, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 24, 2020 08:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...